Inflammation: a novel therapeutic target/direction in atherosclerosis
B Li, W Li, X Li, H Zhou - Current Pharmaceutical Design, 2017 - ingentaconnect.com
Over the past two decades, the viewpoint of atherosclerosis has been replaced gradually by
a lipiddriven, chronic, low-grade inflammatory disease of the arterial wall. Current treatment …
a lipiddriven, chronic, low-grade inflammatory disease of the arterial wall. Current treatment …
[HTML][HTML] Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis
B Li, W Li, X Li, H Zhou - Current Pharmaceutical Design, 2017 - ncbi.nlm.nih.gov
Over the past two decades, the viewpoint of atherosclerosis has been replaced gradually by
a lipid-driven, chronic, low-grade inflammatory disease of the arterial wall. Current treatment …
a lipid-driven, chronic, low-grade inflammatory disease of the arterial wall. Current treatment …
[引用][C] Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis
B Li, W Li, X Li, H Zhou - Current Pharmaceutical Design, 2017 - cir.nii.ac.jp
Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis | CiNii Research CiNii
国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis
B Li, W Li, X Li, H Zhou - Current pharmaceutical design, 2017 - pubmed.ncbi.nlm.nih.gov
Over the past two decades, the viewpoint of atherosclerosis has been replaced gradually by
a lipiddriven, chronic, low-grade inflammatory disease of the arterial wall. Current treatment …
a lipiddriven, chronic, low-grade inflammatory disease of the arterial wall. Current treatment …
[PDF][PDF] Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis
B Lia, W Lib, X Lia, H Zhou - development - pdfs.semanticscholar.org
Over the past two decades, the viewpoint of atherosclerosis has been replaced gradually by
a lipiddriven, chronic, low-grade inflammatory disease of the arterial wall. Current treatment …
a lipiddriven, chronic, low-grade inflammatory disease of the arterial wall. Current treatment …
[PDF][PDF] Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis
B Lia, W Lib, X Lia, H Zhou - development - scholar.archive.org
Over the past two decades, the viewpoint of atherosclerosis has been replaced gradually by
a lipiddriven, chronic, low-grade inflammatory disease of the arterial wall. Current treatment …
a lipiddriven, chronic, low-grade inflammatory disease of the arterial wall. Current treatment …
Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis.
B Li, W Li, X Li, H Zhou - Current Pharmaceutical Design, 2017 - europepmc.org
Over the past two decades, the viewpoint of atherosclerosis has been replaced gradually by
a lipid-driven, chronic, low-grade inflammatory disease of the arterial wall. Current treatment …
a lipid-driven, chronic, low-grade inflammatory disease of the arterial wall. Current treatment …
[PDF][PDF] Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis
B Lia, W Lib, X Lia, H Zhou - development - scienceopen.com
Over the past two decades, the viewpoint of atherosclerosis has been replaced gradually by
a lipiddriven, chronic, low-grade inflammatory disease of the arterial wall. Current treatment …
a lipiddriven, chronic, low-grade inflammatory disease of the arterial wall. Current treatment …